The utility of rapid antigen detection testing for the diagnosis of streptococcal pharyngitis in low-resource settings by Rimoin, Anne W. et al.
International Journal of Infectious Diseases 14 (2010) e1048–e1053The utility of rapid antigen detection testing for the diagnosis of streptococcal
pharyngitis in low-resource settings
Anne W. Rimoin a,*, Christa L. Fischer Walker b, Hala S. Hamza c, Nevine Elminawi d,
Hadeer Abdel Ghafar c, Adriana Vince e, Antonia L.A. da Cunha f, Shamim Qazi g, Dace Gardovska h,
Mark C. Steinhoff b,i
a Department of Epidemiology, UCLA School of Public Health, 650 Charles E. Young Drive S, CHS 41-275, Los Angeles, CA 90095, USA
b Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
c Department of Pediatrics, University of Cairo, Egypt
d Fayoum University, Cairo, Egypt
e Department of Infectology, Zagreb Medical School/Department of Viral Hepatitis, University Hospital for Infectious Diseases, Zagreb, Croatia
f Department of Pediatrics, Federal University of Rio de Janeiro, Brazil
g Department of Child and Adolescent Health and Development, World Health Organization, Geneva, Switzerland
h Department of Pediatrics, Riga Stradins University and Children’s University Hospital, Riga, Latvia
i Children’s Global Health Center, Cincinnati Children’s Hospital, Cincinnati, OH, USA
A R T I C L E I N F O
Article history:
Received 16 October 2009








S U M M A R Y
Objectives: To evaluate the utility of rapid antigen detection testing (RADT) for the diagnosis of group A
streptococcal (GAS) pharyngitis in pediatric outpatient clinics in four countries with varied socio-
economic and geographic profiles.
Methods: We prospectively evaluated the utility of a commercial RADT in children aged 2–12 years
presenting with symptoms of pharyngitis to urban outpatient clinics in Brazil, Croatia, Egypt, and
Latvia between August 2001 and December 2005. We compared the performance of the RADT to culture
using diagnostic and agreement statistics, including sensitivity, specificity, and positive and negative
predictive values. The Centor scores for GAS diagnosis were used to assess the potential effect of
spectrum bias on RADT results.
Results: Two thousand four hundred and seventy-two children were enrolled at four sites. The
prevalence of GAS by throat culture varied by country (range 24.5–39.4%) and by RADT (range 23.9–
41.8%). Compared to culture, RADT sensitivity ranged from 72.4% to 91.8% and specificity ranged from
85.7% to 96.4%. The positive predictive value ranged from 67.9% to 88.6% and negative predictive value
ranged from 88.1% to 95.7%.
Conclusions: In limited-resource regions where microbiological diagnosis is not feasible or practical,
RADTs should be considered an option that can be performed in a clinic and provide timely results.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Group A beta-hemolytic streptococcal (GAS) pharyngitis is a
common illness in children and the most common bacterial cause
of acute pharyngitis worldwide. In affluent countries, the non-
suppurative sequelae of untreated GAS pharyngitis including acute
rheumatic fever (ARF) and rheumatic heart disease (RHD) are now
rare. However, in regions with limited resources, ARF and RHD are
still significant causes of morbidity and mortality, with prevalence
rates that range from 1 to 5 per 1000 school-aged children, leading* Corresponding author.
E-mail address: arimoin@ucla.edu (A.W. Rimoin).
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doi:10.1016/j.ijid.2010.02.2269to more than 400 000 deaths annually.1 In these regions
microbiological culture diagnosis is often not widely available,
and thus most cases of pharyngitis are treated presumptively.
Primary prevention of ARF/RHD is achieved through accurate
diagnosis and treatment of GAS infection. Current North American
strategies for the diagnosis of GAS incorporate the use of clinical
judgment, throat culture and/or rapid antigen tests. The clinical
signs and symptoms of GAS and non-GAS pharyngitis overlap
broadly and can be non-specific. Clinical prediction algorithms
have been evaluated in a variety of settings with limited sensitivity
and specificity for use without laboratory confirmation.2–6 US
practice guidelines recommend that for all pharyngitis cases a
laboratory test should be performed to determine whether GAS are
present in the throat, unless the physician is able to confidentlyses. Published by Elsevier Ltd. All rights reserved.
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grounds.7
Culture of a throat swab on sheep blood agar medium remains
the gold standard for the laboratory diagnosis of GAS pharyngitis.7–
10 However, laboratory infrastructure and the costs and time
associated with throat cultures can present limitations for its use
as a diagnostic tool in low-resource settings. A major disadvantage
of the throat culture is that it takes up to 48 h to obtain a result. In
many low-resource settings, the lag period between specimen
collection and final microbiological diagnosis is particularly
problematic, since it may not be feasible for patients to return
for a follow-up visit and appropriate treatment.
In the 1980s, rapid antigen detection tests (RADT) were
developed to simplify the diagnosis of GAS.11 Compared with
throat culture, RADTs have a high specificity, ranging from 90% to
99%. The sensitivity of RADTs, however, is variable, depending
upon the type of commercial kit used and the study design, ranging
from 75% to 95%.10 This variation in sensitivity has been attributed
to differences in disease spectrum among study populations,
culture methods, and laboratory performance. Given the variation
in reported sensitivity of RADTs, the American Academy of
Pediatrics, the Infectious Diseases Society of America, and the
American Heart Association continue to recommend confirmation
of negative RADT results with throat culture.7–9,12
There is currently no international consensus on the use of
RADTs for the diagnosis of GAS pharyngitis, however these kits
have been widely adopted in Europe and the USA.13 Despite the
variation in sensitivity, there are many advantages to RADTs for the
diagnosis of GAS pharyngitis. They are simple to perform both in
the laboratory and clinic/office setting and the results are available
at the point of care in less than 15 min. Whereas throat cultures
require a microbiology laboratory and a return visit to obtain
results 1–2 days after initial contact with the patient, RADTs
provide rapid diagnosis, which leads to faster, more accurate
treatment, a reduction in indiscriminate antibiotic use, and a
subsequent reduction in the incidence of the non-suppurative
sequelae of untreated GAS pharyngitis.10 RADTs are generally well
characterized, commercially produced to meet uniform standards,
and include internal controls for accuracy of diagnosis. For these
reasons, in low-resource settings where throat culture is not
feasible due to the absence of a laboratory or skilled personnel or
lag time associated with obtaining results, RADTs without the
recommended culture confirmation may still present a practical
alternative to clinical diagnostic algorithms alone.3
To assess the utility of RADTs in varied clinical settings, we
compared the performance of a commercially available rapid
antigen detection test–the STREP A OIA MAX (Thermo Biostar/
Inverness Medical Professional Diagnostics, Princeton, NJ, USA)–
with standard throat culture, in Brazil, Croatia, Latvia, and
Egypt.14–17 To our knowledge, this is the first prospective multi-
country evaluation of a RADT for GAS pharyngitis using a single
standard protocol.
2. Patients and methods
These data were gathered in the context of a multi-country
study designed to evaluate signs and symptoms of GAS pharyngitis
in children and develop new clinical guidelines for the diagnosis of
GAS pharyngitis in low-resource settings where laboratory
confirmation is not always readily available. Data from this study
describing differences in presentation of GAS pharyngitis have
been published elsewhere.4,18
From August 2001 through December 2005, children aged 2–12
years presenting to participating clinics with a complaint of sore
throat were consecutively enrolled in four urban pediatric
outpatient clinics in Rio de Janeiro, Brazil; Zagreb, Croatia; Cairo,Egypt; and Riga, Latvia. A child was excluded if the parent/guardian
reported oral antibiotic use in the three days prior to screening or
parenteral antibiotic use in the 28 days before screening, if there
was a history of rheumatic fever or RHD, or if the child required
hospitalization for any reason at the time of enrollment. All study
sites used a common study protocol and data collection forms. All
data collection forms were translated into the local language.
The study protocol was approved by both local and national
institutional review boards at each of the clinical sites, the World
Health Organization (WHO) in Geneva, and the Committee on
Human Research at the Johns Hopkins Bloomberg School of Public
Health. Informed consent was obtained from the parent or
guardian accompanying the child to the clinic and child assent
was obtained from all children aged 5 years or older.
After patients were enrolled in the study, a physical examination
was performed and demographic and clinical data were collected.
Two throat swabs were taken simultaneously from each patient for
both culture and rapid antigen assay using sterile cotton-tipped
swabs. Throat culture specimens were plated on 5% sheep blood agar
and incubated anaerobically at 37.0 8C; plates were examined at 24
and 48 h for the presence of b-hemolytic streptococci, with
confirmation by bacitracin disk.19 Laboratory staff at each site were
trained using the WHO manual Laboratory diagnosis for group A
streptococcal infections.19 All sites were provided with uniform
training to ensure uniform laboratory procedures for both throat
culture and rapid tests. Regular site visits were made to each
participating laboratory to ensure that standard methods were
being used. The RADT was performed by trained study personnel
according to the instructions in the manufacturer’s package insert.
The RADT has internal positive and negative controls and has a
reported sensitivity range of 79.5–98.1% and specificity of 96.9–
99.0%, compared to throat culture.15–17,20,21
2.1. Statistical methods
Patient demographic and clinical characteristics were com-
pared using Student’s t-tests for continuous variables and Chi-
square analysis for categorical variables. RADT results were
assessed for performance against throat culture results within
each study site using the following diagnostic and agreement
statistics: sensitivity, specificity, positive and negative predictive
values, and diagnostic odds ratio.22 The sensitivity and specificity
of the RADT for the detection of GAS pharyngitis were compared
among study sites using Chi-square tests with a = 0.05 criterion of
significance. Spectrum bias was evaluated by comparing the
performance of the RADT in relationship to disease severity. The
Centor criteria (history of fever, absence of cough, pharyngeal or
tonsillar exudates, and cervical lymphadenopathy) were used to
define the clinical spectrum of acute pharyngitis.23 The Centor
score was defined as the number of criteria present, ranging from
zero to four. Sensitivity and negative predictive values of the RADT
test were calculated on the basis of Centor scores at each study site.
We conducted a Cuzick nonparametric trend test within each site
to compare the sensitivity of the RADT test across sites with
increasing Centor scores. Statistical significance was accepted at
p  0.05, two-tailed. Analyses were carried out with STATA
statistical software, version 10.0.24
3. Results
A total of 2598 children were enrolled in the study (Brazil
n = 294, Croatia n = 404, Egypt n = 1642, Latvia n = 258). One
hundred and twenty-six subjects (110 in Brazil and 16 in Egypt)
were excluded from the analyses due to missing laboratory data,
resulting in a final sample size of 2472 for analysis. A larger
number of patients were recruited from the Egypt site compared to
Table 1
Comparisons of clinical and demographic characteristics by country
All sites Brazil Croatia Egypt Latvia
Total number of patients 2472 184 404 1626 258
Age (years), mean SD 5.20.05 5.8 0.21 5.8 0.14 4.8 0.06 6.61.9
Gender female, n (%) 1070 (43.3) 95 (51.6) 169 (41.8) 687 (42.3) 119 (46.1)
Clinical characteristics, n (%)
History of fever 1997 (80.8) 162 (88.0) 257 (63.6) 1348 (82.9) 230 (89.1)
Absence of cough 1037 (41.9) 80 (43.5) 239 (59.2) 540 (33.2) 178 (69.0)
Pharyngeal or tonsillar exudates 753 (30.5) 52 (28.3) 155 (38.4) 385 (23.7) 161 (62.4)
Cervical lymphadenopathy 686 (27.8) 52 (28.3) 158 (39.1) 291 (17.9) 185 (71.7)
SD, standard deviation.
A.W. Rimoin et al. / International Journal of Infectious Diseases 14 (2010) e1048–e1053e1050the other sites due to the large size of the outpatient clinic and the
experience of the local staff in conducting large clinical studies.
Each study site enrolled patients for at least one full calendar year.
Patient demographic and clinical characteristics varied across
study sites and are shown in Table 1. The mean age of patients
across sites ranged from 4.8 years in Egypt to 6.6 years in Latvia
(p < 0.001).
Table 2 presents microbiological findings and the performance
measures of the RADT as compared to throat culture at each study
site. The proportion of children with a positive GAS throat cultureTable 3
Association between clinical factors and detection of GAS pharyngitis by culture or RA
n
Brazil
History of fever 162
Absence of cough 80
Pharyngeal or tonsillar exudates 52
Cervical lymphadenopathy 52
Croatia
History of fever 257
Absence of cough 239
Pharyngeal or tonsillar exudates 155
Cervical lymphadenopathy 156
Egypt
History of fever 1348
Absence of cough 540
Pharyngeal or tonsillar exudates 385
Cervical lymphadenopathy 291
Latvia
History of fever 230
Absence of cough 178
Pharyngeal or tonsillar exudates 161
Cervical lymphadenopathy 185
GAS, group A Streptococcus; RADT, rapid antigen detection test; OIA MAX, STREP A OI
Results are n (%).
a Statistically significant, p  0.05.
Table 2
Comparisons of microbiological findings among countries
Brazil (n = 184)
GAS prevalence, n (%)
Positive OIA MAX 44 (23.9)
Positive throat culture 45 (24.5)
Discordance,a n (%)
Positive OIA MAX/negative culture 5 (2.7)
Negative OIA MAX/positive culture 6 (3.3)
Concordance,b n (%)
Positive OIA MAX/positive culture 39 (21.2)
Negative OIA MAX/negative culture 134 (72.8)





Diagnostic odds ratio 3.33
OIA MAX, STREP A OIA MAX test; PPV, positive predictive value; NPV, negative predict
a The results of RADT and cultures were discordant in the same patient.
b The results of RADT and cultures were concordant in the same patient.ranged from 24.5% in Brazil to 39.4% in Croatia (p < 0.001). Positive
RADT results also varied by country, ranging from 23.9% in Brazil to
41.8% in Croatia. Concordance between the two test results in the
same patient ranged from 81.8% to 94.0% and discordance ranged
from 5.9% to 18.2%. The sensitivity of the RADT ranged from 72.4%
in Latvia to 91.8% in Croatia and the specificity ranged from 85.7%
in Latvia to 96.4% in Brazil. The positive predictive value and
negative predictive value were highest in Brazil (88.6% and 95.7%,
respectively) and lowest in Latvia (67.9% and 88.1%, respectively).
The diagnostic odds ratio was highest in Brazil.DT
GAS prevalence (culture) GAS prevalence (OIA MAX)
41 (25.3) 42 (25.9)
30 (37.5)a 33 (41.2)a
24 (46.2)a 25 (48.1)
26 (50)a 23 (44.2)a
94 (36.6) 101 (39.3)
110 (46.0)a 111 (46.4)a
62 (40) 69 (44.5)
76 (48.7)a 79 (50.6)a
361 (26.8) 341 (25.3)
430 (79.6)a 173 (32.0)a
121 (31.4)a 123 (31.9)a
96 (33.0)a 106 (36.4)a
67 (29.1) 73 (31.7)
51 (28.7) 57 (32.0)
48 (29.8) 47 (29.2)
59 (31.9)a 59 (31.9)
A MAX test.
Croatia (n = 404) Egypt (n = 1626) Latvia (n = 258)
169 (41.8) 403 (24.8) 81 (31.4)
159 (39.4) 430 (26.4) 76 (29.5)
23 (5.7) 82 (5.0) 26 (10.1)
13 (3.2) 109 (6.7) 21 (8.1)
146 (36.1) 321 (19.7) 55 (21.3)
222 (55.0) 1114 (68.5) 156 (60.5)
91.8 (86.4–95.6) 74.7 (70.3–78.7) 72.4 (60.9–82.0)
90.6 (86.2–94.0) 93.1 (91.6–94.5) 85.7 (79.8–90.5)
86.4 (80.3–91.2) 79.7 (75.4–83.5) 67.9 (56.6–77.8)
94.5 (90.7–97.7) 91.1 (89.3–92.6) 88.1 (82.4–92.5)
0.89 2.97 3.10
ive value; CI, confidence interval; RADT, rapid antigen detection test.
Table 4
Sensitivity and negative predictive values of RADT as stratified by the Centor criteria scoresa
Centor score
0 1 2 3 4
Brazil (n = 184)
No. of patients (% total) 10 (5.4) 68 (37.0) 58 (31.5) 30 (16.3) 18 (9.8)
Positive OIA MAX, n (%) 0 (0) 5 (7.3) 11 (19.0) 16 (53.3) 12 (66.7)
Positive cultures, n (%) 0 (0) 7 (10.3) 12 (20.7) 14 (46.7) 12 (66.7)
Sensitivity, % (95% CI) – 42.9 (9.9–81.6) 83.3 (51.6–97.9) 100 (76.8–100) 100 (73.5–100)
NPV, % (95% CI) – 93.7 (84.5–98.2) 95.7 (85.5–99.5) 100 (76.8–100) 100 (54.1–100)
Croatia (n = 404)
No. of patients (%) 28 (6.9) 98 (24.3) 151 (37.4) 101 (25) 26 (6.4)
Positive OIA MAX, n (%) 10 (35.7) 34 (34.7) 64 (42.4) 46 (45.5) 15 (57.7)
Positive cultures, n (%) 8 (28.6) 29 (29.6) 66 (43.7) 43 (42.6) 13 (50)
Sensitivity, % (95% CI) 100 (63.1–100) 93.1 (77.2–99.2) 87.9 (77.5–94.6) 93.0 (80.9–98.5) 100 (75.3–100)
NPV, % (95% CI) 100 (81.5–100) 89.9 (80.2–95.8) 90.8 (82.7–95.9) 94.5 (84.9–98.9) 100 (71.5–100)
Egypt (n = 1626)
No. of patients (%) 138 (8.5) 725 (44.6) 504 (31.0) 205 (12.6) 54 (3.3)
Positive OIA MAX, n (%) 25 (18.1) 142 (19.6) 134 (26.6) 75 (36.6) 27 (50)
Positive cultures, n (%) 29 (21.0) 164 (22.6) 364 (72.2) 80 (39.0) 18 (33.3)
Sensitivity, % (95% CI) 69.0 (49.2–84.7) 72.0 (64.4–78.7) 73.4 (65.2–80.5) 80.0 (69.6–88.1) 94.4 (72.7–99.9)
NPV, % (95% CI) 92.0 (85.4–96.3) 92.1 (89.6–94.2) 90.0 (86.4–92.8) 87.7 (80.8–92.8) 96.3 (81.0–99.9)
Latvia (n = 258)
No. of patients (%) 3 (1.2) 34 (13.2) 95 (36.8) 112 (43.4) 14 (5.4)
Positive OIA MAX, n (%) 1 (33.3) 8 (23.5) 33 (34.7) 36 (32.1) 3 (21.4)
Positive cultures, n (%) 1 (33.3) 9 (26.5) 28 (29.5) 34 (30.4) 4 (28.6)
Sensitivity, % (95% CI) 100 (2.5–100) 55.6 (21.2–86.3) 78.6 (59.0–91.7) 70.6 (52.5–84.9) 75 (19.4–99.4)
NPV, % (95% CI) 100 (15.8–100) 84.6 (65.1–95.6) 90.3 (80.1–96.4) 86.8 (77.1–93.5) 90.9 (58.7–99.8)
RADT, rapid antigen detection test; OIA MAX, STREP A OIA MAX test; NPV, negative predictive value; CI, confidence interval.
a Centor criteria are history of fever, absence of cough, presence of pharyngeal or tonsillar exudates, and presence of cervical lymphadenopathy.
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of signs and symptoms associated with clinical presentation of
pharyngitis between countries (Table 3). Cervical lymphadenopa-
thy was the only sign that was consistently statistically associated
with positive GAS culture at all sites. We did not find a statistical
association between the severity of symptoms (based on Centor
scores) and RADT sensitivity at any of the participating sites (Brazil
p = 0.1, Croatia p = 0.166, Egypt p = 0.083, Latvia p = 0.488), as
shown in Table 4.
4. Discussion
RADTs have been widely evaluated in various clinical settings,
however standardized data from low-resource settings are scant.
This study is the first multi-country evaluation of the utility of
RADTs for Streptococcus, using a single test and standard protocol
at all sites. Previous evaluations of the OIA MAX test in the USA
have demonstrated a range of sensitivity from 79.3% to 94.7% and
specificity from 96.3% to 100%.15,25–29 Our study demonstrated a
range of sensitivity from 72.4% to 91.8% and specificity from 85.7%
to 96.4%. The high negative predictive value in all countries
suggests that a negative test would be useful to rule out GAS
pharyngitis and potentially reduce unnecessary antibiotic treat-
ment. The diagnostic odds ratio was highest in Brazil (3.33) and
lowest in Croatia (0.89). The Croatian diagnostic odds ratio was less
than 1, which is atypical, but occurs when the sensitivity is higher
than the specificity.
Recent studies have reported that the sensitivity of RADTs may
be affected by variation in the spectrum of clinical disease severity
or presentation.30–32 The sensitivity of RADTs has been reported to
range from 47% to 65% when applied to patients with a low
probability of GAS pharyngitis based on clinical findings. As
the probability of GAS pharyngitis increases (based on the number
of clinical criteria present), so does the sensitivity of the
RADT.30,31,33,34 This spectrum bias was not observed in our study.
We found no statistically significant association between the RADT
sensitivity and the spectrum of clinical presentation based on the
Centor criteria at any single site or at all sites combined.35 Thesedata are consistent with a recent study of the same RADT in a US
population.33
Throat cultures are currently considered the gold standard for
diagnosis of GAS pharyngitis; however in settings with limited
resources and higher incidences of post-streptococcal cardiac
sequelae, as in many economically developing regions, bacterial
culture is neither available nor feasible. In these regions, clinicians
currently have the choice of treating everyone, treating no one, or
utilizing clinical guidelines/rules, which have been shown to vary
widely in terms of sensitivity and specificity by region and are
subject to the clinical interpretation of nonspecific signs and
symptoms.2–5,18 Current US guidelines recommend confirmation
of negative rapid antigen test results with a throat culture, which is
considered to have better sensitivity than rapid tests. In our study
of more than 2400 children, only a small percentage of patients
(3.2–8.1%) were misclassified as GAS-negative by RADT as
compared to the local throat culture, which represents the
GAS-positive cases that would have been missed without the
recommended confirmatory throat culture and may be at risk of
the suppurative sequelae of untreated GAS. Misclassification of
individuals who were identified as GAS-positive by RADT and GAS-
negative by throat culture was also minimal, ranging from 2.7% to
10.1% across sites. These cases represent the individuals who
would be ‘unnecessarily-treated’ using the RADT as compared to
throat culture. It is notable that the stratification by Centor scores
demonstrated a similar range of misclassification for those
individuals who were RADT-negative/throat culture-positive,
though the RADT still performed slightly better at each site;
however the misclassification of individuals who were RADT-
positive/throat culture-negative was consistently high for all sites,
with over-treating of up to 60% of patients who did not need
antibiotics by local culture criteria.
Cost–benefit analyses have demonstrated that treating all
patients with pharyngitis without microbiological confirmation
(RADT or culture) would prevent up to 90% of the potential
complications related to RHD, which may require costly surgical
interventions.36 Although a treat-everyone strategy is common,
and may reduce the incidence of RHD, there will be substantial
A.W. Rimoin et al. / International Journal of Infectious Diseases 14 (2010) e1048–e1053e1052unnecessary use of antibiotics. Indiscriminate use of antibiotics
may result in unnecessary adverse reactions, increased antibiotic
resistance in both Streptococcus and other upper airway organ-
isms, and therefore increased healthcare costs. RADTs may provide
significant cost–benefit advantages if the test sensitivity is
adequately high.36–38 In the USA, as at our participating sites,
the cost of a RADT (US$5–10) is somewhat lower than the cost of a
throat culture (US$15–20).39 For example, in Brazil a throat culture
is approximately US$5.55 whereas a RADT is US$2.77 (personal
communication A.L. da Cunha). In Latvia, throat cultures cost
US$12.66 as compared to US$4.49 for RADT (personal communi-
cation D. Gardovska).
There were several limitations to our study. First, this particular
commercial RADT has recently been discontinued in the USA and is
no longer available. However, the principle of assessing the utility
of any RADT would be similar, as would be the logic for using a
RADT with similar performance characteristics in clinics in
limited-resource settings. Second, the microbiological culture
results may not have been comparable since they were performed
in a variety of laboratories in different countries. Throat culture
performance is affected by a number of factors including: swab
technique, the skill of the personnel who process and interpret
blood agar plate cultures, the skill and experience of the laboratory,
and the specific materials and conditions used for plating and
incubation of the cultures.20,40 Discordance between the results of
simultaneous cultures in the same laboratory is well described in
the literature.32 Assessment of RADT performance is affected by
the same issues that affect culture results, however many RADT
tests are easier to perform and have internal controls, which
minimizes errors. Third, the observed differences in clinical
presentation between sites could reflect a selection bias during
the recruitment process, differences in access to care, or the
parental threshold for care-seeking at each site. To minimize bias
and differences in site performance, we provided uniform training
and standardized manuals and conducted multiple site visits.
Fourth, it is likely that some of the individuals enrolled in our study
were carriers rather than acutely infected with GAS. Neither
conventional throat culture nor RADTs can differentiate acute GAS
pharyngitis from GAS carriers with intercurrent viral pharyngitis.
The comparison is valid and a positive result with either test is
accepted as a presumptive criterion for treatment for GAS
infection.10 Finally, we were not able to compare sensitivity and
specificity of the RADT directly with the sensitivity and specificity
of the throat culture across all four countries, as we did not have a
third gold standard test (such as a single reference laboratory
processing of all throat cultures). However, we did compare the
two tests within each country.
5. Conclusions
Given the lower sensitivity of RADTs as compared to throat
culture, the current US recommended practice of conducting
throat culture confirmation following negative RADT results
should be maintained in settings where the resources to perform
bacteriological diagnosis are available, return rates for results are
high, and appropriate treatment is likely. Nonetheless, the present
evaluation suggests that RADTs may have utility in a variety of
low- and middle-income country settings. In low-resource settings
where laboratory testing is not available, RADTs may be the only
feasible solution for rapid, standardized diagnosis of GAS. RADTs
may provide quick and accurate diagnosis in lower-level health-
care centers, thus eliminating the need for referrals to higher-level
clinics or costly return visits to access test results. In many
communities where distances to the closest health facilities are
great, healthcare providers are often limited to a single point of
contact with the patient to ensure proper treatment.Our study results suggest that in settings where throat cultures
are not feasible, the use of RADTs may provide a reasonable
alternative to over-prescription of antibiotics to all children who
present with clinical sore throat and a significant improvement
over using clinical prediction algorithms for standardized diagno-
sis. Since RADTs require little or no laboratory infrastructure and
can provide rapid results, an affordable RADT that could be used in
resource-limited settings should be developed as an important tool
to reduce the burden of rheumatic fever and rheumatic heart
disease. Cost effectiveness studies are needed to evaluate the cost–
benefit of introducing RADTs into resource-limited settings,
compared to investing in laboratories for throat cultures or the
cost of universal antibiotic treatment for sore throat, or chronic
rheumatic heart disease care.
Additionally, these data suggest that a RADT may be useful as an
independent standard in select circumstances. GAS pharyngitis
results obtained from a throat culture will be influenced by the
technique of obtaining the throat swab, the swab used, and
variation in microbiology laboratory culture media and proce-
dures, all of which will vary in different settings.41 Although RADT
results may also be subject to variation in the technique used to
obtain the throat swabs, RADTs are likely to have less variance due
to standardized commercial production and internal controls in
the kit. This may be especially beneficial in multi-site clinical
studies of GAS pharyngitis, for which standardization is logistically
difficult.
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